Paper Details

  1. Home
  2. Paper Details

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.

Author: FoxNorma Lynn, GordonDavid, GroarkJames, HammerAnne E, RothDavid, SheikhSaira Z, StruemperHerbert

Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Patients with systemic lupus erythematosus (SLE) successfully self-administered belimumab subcutaneously (SC) using a novel autoinjector. The pharmacokinetic profile was stable following a switch from intravenous (IV) administration with acceptable adverse events and pain levels. The recommended dosing interval between IV to SC dosing is 1 - 4 weeks.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To study self-administration and pharmacokinetics (PK) of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). METHODS: Patients previously treated with belimumab self-administered belimumab 200 mg SC weekly for 8 weeks using an autoinjector. The primary endpo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100660/

データ提供：米国国立医学図書館（NLM）

Belimumab Self-Administration: A Convenient and Effective Option

Self-administration of medications can empower patients, allowing them to take control of their health and treatment. This study evaluates a novel autoinjector for subcutaneous self-administration of belimumab, a treatment for systemic lupus erythematosus (SLE), investigating its feasibility, effectiveness, and safety.

Belimumab Self-Administration: A Success

The study demonstrates the successful self-administration of belimumab using the novel autoinjector, with high success rates across all stages of the trial. Patients reported minimal injection-site pain and experienced a stable pharmacokinetic profile following the switch from intravenous to subcutaneous administration.

Empowering Patients with Convenient Treatment Options

This study highlights the potential benefits of self-administration for patients with SLE, offering a convenient and effective option for managing their condition. It empowers patients by giving them greater control over their treatment and potentially improving their overall quality of life.

Dr. Camel's Conclusion

Just like a camel navigating a vast desert, patients with SLE often face challenges in managing their condition. This study offers a promising solution, enabling patients to take control of their treatment with ease and convenience. It's a significant step towards empowering patients and enhancing their well-being.
Date :
  1. Date Completed 2017-01-13
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

27668697

DOI: Digital Object Identifier

PMC5100660

Related Literature

Article Analysis
・Effects of belimumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.